Drug Profile
Research programme: protein phosphokinase inhibitors - IngenOx Therapeutics
Alternative Names: CT 300Latest Information Update: 11 Jan 2023
Price :
$50
*
At a glance
- Originator Celleron Therapeutics
- Developer IngenOx Therapeutics
- Class Small molecules
- Mechanism of Action Phosphokinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 05 Jan 2023 Argonaut Therapeutics has merged with Celleron Therapeutics to form IngenOx Therapeutics
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in United Kingdom
- 14 Nov 2007 Compounds from this research programme are available for licensing (http://cellerontherapeutics.com)